Home World News FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma World News FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma By Ogkologos - May 23, 2025 647 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study AK105-304 and Study AK105-202 Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR “Solid Stress” Keeps Immune System from Killing Off Cancer Cells in... July 21, 2021 New on NCI’s Websites for April 2024 April 12, 2024 Քաղցկեղն իմ համայնքում՝ Քաղցկեղով երեխաների բուժումը Հայաստանում May 13, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Selpercatinib December 16, 2020 Load more HOT NEWS Tattoo Ink May Show Up as Suspicious Spots in Lymph Nodes... EMA Recommends Extension of Indications for Nivolumab to Include First-Line Treatment... Five-Year Outcomes with CAR T Cell Therapy FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
